misonidazole has been researched along with buparlisib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, KM; Campo, L; Fenwick, JD; Gleeson, FV; Green, M; Higgins, GS; Horne, A; Macpherson, RE; Maughan, TS; McCole, MG; McGowan, DR; McKenna, WG; Mohammed, S; Muschel, RJ; Ng, SM; Panakis, N; Prevo, R; Skwarski, M; Strauss, VY; Stuart, R; Tacconi, EMC; Vallis, KA | 1 |
1 trial(s) available for misonidazole and buparlisib
| Article | Year |
|---|---|
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anorexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fatigue; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Morpholines; Nausea; Phosphoinositide-3 Kinase Inhibitors; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiotherapy; Tumor Hypoxia | 2019 |